Radiation pneumonitis in patients with non-small-cell lung cancer treated with erlotinib concurrent with thoracic radiotherapy

Journal of Thoracic Oncology

Volumn 9, Issue 6, 2014, Pages 882-885

  Zhuang, Hongqing ^a   Yuan, Zhiyong ^a   Chang, Joe Y ^b   Wang, Jun ^a   Pang, Qingsong ^a   Zhao, Lujun ^a   Wang, Ping ^a  

^a KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Erlotinib; NSCLC; Radiation pneumonitis; Thoracic radiotherapy

Indexed keywords

ERLOTINIB; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; DISEASE SEVERITY; FATALITY; FEMALE; HUMAN; INCIDENCE; INOPERABLE CANCER; INTENSITY MODULATED RADIATION THERAPY; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; RADIATION PNEUMONIA; VERY ELDERLY; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; LUNG NEOPLASMS; MIDDLE AGED; RADIATION PNEUMONITIS; RADIOGRAPHY; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; QUINAZOLINES; RADIATION PNEUMONITIS; SEVERITY OF ILLNESS INDEX;

EID: 84901476004     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000126     Document Type: Article

References (15)

1. Schneider CP, Heigener D, Schott-von-Römer K, et al. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from German centers in the TRUST study. J Thorac Oncol 2008;3:1446-1453.
2. Cappuzzo F, Ciuleanu T, Stelmakh L, et al.; SATURN Investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-529.
3. Zhuang H, Wang J, Zhao L, Yuan Z, Wang P. The theoretical foundation and research progress for WBRT combined with erlotinib for the treatment of multiple brain metastases in patients with lung adenocarcinoma. Int J Cancer 2013;133:2277-2283.
4. Arriagada R, Auperin A, Burdett S, et al; NSCLC Meta-analyses Collaborative Group. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta- analyses of individual patient data. Lancet 2010;375:1267-1277.
5. Aupérin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010;28:2181-2190.
6. Roelandts M, Moretti L, Van Houtte P. [Postoperative radiotherapy in non-small cell lung cancer]. Cancer Radiother 2011;15:514-517.
7. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-181. (Pubitemid 36962641)
8. Shapiro DL, Finkelstein JN, Rubin P, Penney DP, Siemann DW. Radiation induced secretion of surfactant from cell cultures of type II pneumocytes: an in vitro model of radiation toxicity. Int J Radiat Oncol Biol Phys 1984;10:375-378. (Pubitemid 14110172)
9. Vasié L, Durdevié P. Radiation-induced lung damage-etiopathogenesis, clinical features, imaging findings and treatment. Med Pregl 2012;65:319-25.
10. Kong FM, Ten Haken R, Eisbruch A, Lawrence TS. Non-small cell lung cancer therapy-related pulmonary toxicity: an update on radiation pneumonitis and fibrosis. Semin Oncol 2005;32(2 Suppl 3):S42-S54.
11. Ren S, Li Y, Li W, Zhao Z, Jin C, Zhang D. Fatal asymmetric interstitial lung disease after erlotinib for lung cancer. Respiration 2012;84:431-435.
12. Tsubata Y, Hamada A, Sutani A, Isobe T. Erlotinib-induced acute interstitial lung disease associated with extreme elevation of the plasma concentration in an elderly non-small-cell lung cancer patient. J Cancer Res Ther 2012;8:154-156.
13. Wang J, Xia TY, Wang YJ, et al. Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non- small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011;81:e59-e65.
14. Nanda A, Dias-Santagata DC, Stubbs H, et al. Unusual tumor response and toxicity from radiation and concurrent erlotinib for non-small-cell lung cancer. Clin Lung Cancer 2008;9:285-287.
15. Chang CC, Chi KH, Kao SJ, et al. Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono- institutional experience. Lung Cancer 2011;73:189-194.